Merck COVID-19 oral drug has an effective rate of only 30%?
- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
- HIV infection may shorten a person’s life expectancy by about 5 years
- Moderna CEO: The COVID-19 vaccine will be updated every year like the iPhone 1 dose per year
- UK approved the world’s first vaccine for COVID-19 Omicron
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
Merck COVID-19 oral drug has an effective rate of only 30%?
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Merck COVID-19 oral drug has an effective rate of only 30%?
On November 26, 2021, Merck and Ridgeback announced updated clinical data for the COVID-19 oral drug Molnupiravir for the treatment of mild to moderate COVID-19s.
According to the data of all admitted patients, reduce the hospitalization rate or mortality rate by 30%. There were 9 deaths in the placebo group and 1 in the treatment group.
On October 1, 2021, Merck and Ridgeback announced the phase III clinical interim data of Molnupiravir in the treatment of patients with mild to moderate COVID-19 pneumonia .
The hospitalization or mortality rate of the Molnupiravir treatment group was 7.3% (28/385), and the hospitalization or mortality rate of the control group was 7.3% (28/385). The mortality rate was 14.1% (53/377).
Molnupiravir reduced hospitalization or mortality by 50%, with a p value of 0.0012.
In terms of mortality, there were no deaths in the treatment group and 8 deaths in the control group. (See: Molnupiravir, a special oral drug for the treatment of COVID-19 pneumonia by Merck, has achieved good results, reducing hospitalization or mortality by 50%, and may be one of the decisive drugs for the treatment of COVID-19 pneumonia in the future )
Moreover, the UK is the first in the world to approve the listing of Molnupiravir in the UK. See: The UK approves Merck’s COVID-19 oral drug Molnupiravir, opening a new era of crown treatment! Is this embarrassing capitalized?
The Molnupiravir update has an effective rate of only 30% for all patients, which is far lower than the 50% in the interim analysis.
Affected by this news, Merck’s pre-market share price fell 4%, competitor Pfizer’s pre-market share price rose 6%, mRNA vaccine company Moderna’s share price rose 13%, and BioNtech’s share price rose 10%.
Summary
In the past two months, the mood about the COVID-19 epidemic has repeatedly changed in hope and anxiety, and the stock prices of relevant pharmaceutical companies have also fluctuated.
The success of Merck and Pfizer’s COVID-19 oral medicine has greatly increased confidence in defeating the epidemic. However, the epidemic does not seem to go away easily.
The effective rate of Merck’s oral medicine has dropped sharply.
The new mutant strain B.1.1.519 in South Africa may be a super mutant, which once again caused widespread anxiety.
Merck COVID-19 oral drug has an effective rate of only 30%?
(source:internet, reference only)
Disclaimer of medicaltrend.org
